Page 2 - Codex Dna News Today

Codex DNA (NASDAQ:DNAY – Get Rating) issued its quarterly earnings data on Wednesday. The company reported ($0.45) EPS for the quarter, topping analysts’ consensus estimates of ($0.50) by $0.05, MarketWatch Earnings reports. Codex DNA had a negative return on equity of 43.84% and a negative net margin of 311.52%. Shares of NASDAQ:DNAY traded up $0.11 […]

Codex DNA (NASDAQ:DNAY – Get Rating) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research note issued to investors on Friday, Zacks.com reports. According to Zacks, “Codex DNA Inc. is a creator of the BioXp(TM) system, a fully automated benchtop instrument which enables numerous synthetic biology workflows. […]

Codex DNA (NASDAQ:DNAY – Get Rating) and Rapid Micro Biosystems (NASDAQ:RPID – Get Rating) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, valuation, earnings, institutional ownership and dividends. Profitability This table compares Codex DNA and Rapid […]

Codex DNA, Inc. (NASDAQ:DNAY – Get Rating) was the target of a large growth in short interest in March. As of March 31st, there was short interest totalling 1,980,000 shares, a growth of 37.5% from the March 15th total of 1,440,000 shares. Based on an average daily volume of 380,900 shares, the days-to-cover ratio is […]

Codex DNA (NASDAQ:DNAY – Get Rating) and Rapid Micro Biosystems (NASDAQ:RPID – Get Rating) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, risk, dividends, institutional ownership, earnings, profitability and valuation. Earnings & Valuation This table compares Codex DNA […]

Codex DNA (NASDAQ:DNAY – Get Rating) issued its quarterly earnings results on Tuesday. The company reported ($0.43) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.37) by ($0.06), MarketWatch Earnings reports. Codex DNA updated its FY 2022 guidance to EPS. DNAY traded down $0.76 on Thursday, hitting $5.30. 1,160,977 shares of […]

SAN DIEGO, March 02, 2022 -- Codex DNA, Inc. , a pioneer in automated benchtop synthetic biology systems, today announced that it will release its fourth quarter 2021 financial results on Tuesday,... | March 2, 2022

Codex DNA Announces Pricing of Initial Public Offering June 17, 2021 22:16 ET | Source: Codex DNA, Inc. Codex DNA, Inc. San Diego, California, UNITED STATES SAN DIEGO, June 17, 2021 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (“Codex DNA”), creators of the BioXp™ system, a fully automated benchtop instrument that enables numerous synthetic biology workflows, today announced the pricing of its initial public offering of 6,666,665 shares of its common s...